Logo image of IKT

INHIBIKASE THERAPEUTICS INC (IKT) Stock Fundamental Analysis

USA - NASDAQ:IKT - US45719W2052 - Common Stock

1.6 USD
+0.08 (+5.26%)
Last: 11/18/2025, 8:14:31 PM
1.6 USD
0 (0%)
After Hours: 11/18/2025, 8:14:31 PM
Fundamental Rating

3

IKT gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 533 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for IKT as it has an excellent financial health rating, but there are worries on the profitability. IKT has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year IKT has reported negative net income.
IKT had a negative operating cash flow in the past year.
In the past 5 years IKT always reported negative net income.
In the past 5 years IKT always reported negative operating cash flow.
IKT Yearly Net Income VS EBIT VS OCF VS FCFIKT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -5M -10M -15M -20M -25M

1.2 Ratios

Looking at the Return On Assets, with a value of -46.71%, IKT is in line with its industry, outperforming 52.91% of the companies in the same industry.
With a decent Return On Equity value of -51.85%, IKT is doing good in the industry, outperforming 65.10% of the companies in the same industry.
Industry RankSector Rank
ROA -46.71%
ROE -51.85%
ROIC N/A
ROA(3y)-77.15%
ROA(5y)-57.11%
ROE(3y)-96.05%
ROE(5y)-71.15%
ROIC(3y)N/A
ROIC(5y)N/A
IKT Yearly ROA, ROE, ROICIKT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -5K -10K

1.3 Margins

IKT does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IKT Yearly Profit, Operating, Gross MarginsIKT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5K -10K -15K

More info and screens

8

2. Health

2.1 Basic Checks

IKT does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, IKT has more shares outstanding
The number of shares outstanding for IKT has been increased compared to 5 years ago.
There is no outstanding debt for IKT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
IKT Yearly Shares OutstandingIKT Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
IKT Yearly Total Debt VS Total AssetsIKT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

IKT has an Altman-Z score of 5.30. This indicates that IKT is financially healthy and has little risk of bankruptcy at the moment.
IKT has a better Altman-Z score (5.30) than 75.61% of its industry peers.
There is no outstanding debt for IKT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 5.3
ROIC/WACCN/A
WACC8.77%
IKT Yearly LT Debt VS Equity VS FCFIKT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M 40M 60M 80M

2.3 Liquidity

A Current Ratio of 10.09 indicates that IKT has no problem at all paying its short term obligations.
IKT's Current ratio of 10.09 is amongst the best of the industry. IKT outperforms 81.24% of its industry peers.
IKT has a Quick Ratio of 10.09. This indicates that IKT is financially healthy and has no problem in meeting its short term obligations.
IKT's Quick ratio of 10.09 is amongst the best of the industry. IKT outperforms 81.43% of its industry peers.
Industry RankSector Rank
Current Ratio 10.09
Quick Ratio 10.09
IKT Yearly Current Assets VS Current LiabilitesIKT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

1

3. Growth

3.1 Past

IKT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 66.04%, which is quite impressive.
The Revenue for IKT has decreased by -100.00% in the past year. This is quite bad
EPS 1Y (TTM)66.04%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%80%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 19.76% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y79.72%
EPS Next 2Y30.83%
EPS Next 3Y19.76%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
IKT Yearly Revenue VS EstimatesIKT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 1M 2M 3M 4M
IKT Yearly EPS VS EstimatesIKT Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 -1 -2 -3 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

IKT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year IKT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IKT Price Earnings VS Forward Price EarningsIKT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IKT Per share dataIKT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1

4.3 Compensation for Growth

IKT's earnings are expected to grow with 19.76% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y30.83%
EPS Next 3Y19.76%

More info and screens

0

5. Dividend

5.1 Amount

IKT does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

INHIBIKASE THERAPEUTICS INC

NASDAQ:IKT (11/18/2025, 8:14:31 PM)

After market: 1.6 0 (0%)

1.6

+0.08 (+5.26%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14 2025-11-14/amc
Earnings (Next)03-25 2026-03-25/amc
Inst Owners66.02%
Inst Owner Change0.76%
Ins Owners3.19%
Ins Owner Change0%
Market Cap119.23M
Revenue(TTM)N/A
Net Income(TTM)-41.51M
Analysts80
Price Target8.16 (410%)
Short Float %5.1%
Short Ratio25.03
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-40.66%
Min EPS beat(2)-60.3%
Max EPS beat(2)-21.01%
EPS beat(4)0
Avg EPS beat(4)-156.61%
Min EPS beat(4)-471.19%
Max EPS beat(4)-21.01%
EPS beat(8)4
Avg EPS beat(8)-70.75%
EPS beat(12)6
Avg EPS beat(12)-48.96%
EPS beat(16)7
Avg EPS beat(16)-39.37%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-39.29%
EPS NY rev (1m)-2%
EPS NY rev (3m)-19.53%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.49
P/tB 1.49
EV/EBITDA N/A
EPS(TTM)-0.91
EYN/A
EPS(NY)-0.73
Fwd EYN/A
FCF(TTM)-0.27
FCFYN/A
OCF(TTM)-0.27
OCFYN/A
SpS0
BVpS1.07
TBVpS1.07
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -46.71%
ROE -51.85%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-77.15%
ROA(5y)-57.11%
ROE(3y)-96.05%
ROE(5y)-71.15%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 851.22%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 10.09
Quick Ratio 10.09
Altman-Z 5.3
F-Score4
WACC8.77%
ROIC/WACCN/A
Cap/Depr(3y)802.67%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)66.04%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%80%
EPS Next Y79.72%
EPS Next 2Y30.83%
EPS Next 3Y19.76%
EPS Next 5YN/A
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-132.5%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-2.77%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-1.56%
OCF growth 3YN/A
OCF growth 5YN/A

INHIBIKASE THERAPEUTICS INC / IKT FAQ

What is the ChartMill fundamental rating of INHIBIKASE THERAPEUTICS INC (IKT) stock?

ChartMill assigns a fundamental rating of 3 / 10 to IKT.


What is the valuation status for IKT stock?

ChartMill assigns a valuation rating of 0 / 10 to INHIBIKASE THERAPEUTICS INC (IKT). This can be considered as Overvalued.


What is the profitability of IKT stock?

INHIBIKASE THERAPEUTICS INC (IKT) has a profitability rating of 1 / 10.


What is the expected EPS growth for INHIBIKASE THERAPEUTICS INC (IKT) stock?

The Earnings per Share (EPS) of INHIBIKASE THERAPEUTICS INC (IKT) is expected to grow by 79.72% in the next year.